Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label Phase II Clinical Trial to Test the Efficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma

NCT07263438 is registered in ClinicalTrials.gov with Centre Hospitalier Universitaire Vaudois as lead sponsor.

NCT NCT07263438
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07263438 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label Phase II Clinical Trial to Test the Efficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma
Lead sponsor
Centre Hospitalier Universitaire Vaudois
Phase
Phase 2
Overall status
Recruiting
Start date
November 3, 2025
Completion date
December 31, 2030
Enrollment
59 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma, recurrence tumor